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http://www.biomedcentral.com/1471-2407/13/519RESEARCH ARTICLE Open AccessCardiopulmonary bypass has a modest
association with cancer progression: a
retrospective cohort study
Cathy Anne Pinto1*, Stephen Marcella1, David A August2, Bart Holland3, John B Kostis4 and Kitaw Demissie1,5Abstract
Background: Given their frequency of occurrence in the United States, cancer and heart disease often coexist. For
patients requiring open-heart surgery, this raises concern that the use of cardiopulmonary bypass (CPB) may cause
a transient immunosuppression with the potential to promote the spread and growth of coexisting cancer cells.
This study examined the association of cardiopulmonary bypass with cancer progression in a large population-
based setting using linked data from several state-wide registries.
Methods: A retrospective cohort study of cancer risk, stage, and mortality in 43,347 patients who underwent
coronary artery bypass graft (CABG) surgery with and without CPB in New Jersey between 1998–2004 was
conducted. A competing risk analogue of the Cox proportional hazards model with propensity score adjustment
and regression on the cause-specific hazard was used to compute relative risk ratios (95% confidence intervals [CIs])
for patients undergoing CABG surgery with and without CPB.
Results: An increased risk for overall cancer incidence (17%) and cancer-specific mortality (16% overall, 12% case
fatality) was observed; yet these results did not reach statistical significance. Of 11 tumor-specific analyses, an
increased risk of skin melanoma (1.66 [95% CI, 1.08-2.55: p=0.02]) and lung cancer (1.36 [95% CI, 1.02-1.81: p=0.03])
was observed for patients with pump versus off-pump open-heart surgery. No association was found with cancer
stage.
Conclusions: These results suggest that there may be a relationship between CPB and cancer progression.
However, if real, the effect is likely modest at most. Further research may still be warranted with particular focus on
skin melanoma and lung cancer which had the strongest association with CPB.
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Cardiac disease and cancer occur commonly in the
United States, and it is therefore not infrequent that
patients who undergo open heart surgery also develop
cancer. Cancer therapy generally should be performed as
soon as possible after diagnosis, except in cases where
surgery may take priority for patients who are at high
risk of suffering a more imminent major cardiac event.
Open-heart surgery with cardiopulmonary bypass (CPB)
is known to cause a transient immunosuppression, as evi-
denced by increases in immunoregulatory factors including* Correspondence: cathy.pinto@merck.com
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reproduction in any medium, provided the orIL-10, a major immunoregulatory cytokine with inhibitory
effects of IFN-γ, tumor necrosis factor, IL-1, IL-6, and IL-8.
CPB has also been shown to increase TGF-β, a cytokine
with several potent immunosuppressive and immunomod-
ulatory effects that may contribute to negative feedback
regulation of T cell-mediated immune response [1,2]. It is
therefore possible that such biochemical changes may lead
to clinically relevant changes in immune system function
and cancer surveillance with the potential to promote the
spread and growth of co-existing cancer cells [1,2]. Al-
though changes in immunoregulatory factors caused by
CPB are short-lived and not likely to induce carcinogen-
esis, it is plausible that CPB may be linked to cancer pro-
gression. Further research is warranted, and may providetd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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patients with cardiovascular co-morbidities.
Few studies have examined the association between
CPB and cancer progression. A recent posthoc analysis
of 611 patients by Vieira et. al. examined the association
of cardiac and non-cardiac mortality with coronary
artery bypass surgery with CPB and non-surgical inter-
ventions (PCI, medical treatment) [3]. Compared with
the non-surgical controls, CPB surgery was associated
with a lower incidence of cardiac death (76.8% and
47.1%, respectively) and higher incidence of non-cardiac
mortality, with a higher tendency toward cancer related
death (7.2% and 20.6%, respectively). Two other recent
studies examined the effects of CPB after cancer diagno-
sis on all-cause and cancer-specific mortality rates [4,5].
The results demonstrated that all-cause and cancer-
specific mortality after CPB increased with shorter time
intervals between diagnosis and the surgical interven-
tion, especially for those patients with less than 2 years
between the cancer diagnosis and subsequent cardiac
procedure (p<0.0001).
Although data suggests an association between CPB
and cancer progression, these results have not been con-
sistently demonstrated. A study by Platell and colleagues
in 33 patients with histologically proven colorectal showed
a lower 5-year colon cancer-specific survival rate for those
who underwent CPB surgery than for non-surgical con-
trols: 34% and. 71%, respectively, p<0.05; HR=2.9 (95% CI:
1.5-4.4). However, a sensitivity analysis that excluded pa-
tients with Stage IV cancer (1 CPB patient, 1 control)
showed no significant difference in the cancer-specific sur-
vival rate (p=0.1) [6]. Additionally, in a recent multicenter
study of CPB and cancer progression performed by Suzuki
et. al. in 74 patients with metastatic cancer who under-
went open-heart surgery with and without CPB, no signifi-
cant difference was observed in cancer-specific mortality
(26.7% and 24.1%, respectively, p=0.8) [7].
Further research is warranted to enable a robust assess-
ment of the association between CPB and cancer progres-
sion. The aim of the present study is to evaluate cancer
incidence, stage, and cancer-specific mortality in a large
population-based cohort who previously underwent open
heart surgery with and without CPB using linked data
from several state-wide registries.
Methods
Population and data source
The study population included patients who underwent
at least one open-heart coronary artery bypass surgery
(CABG), with no incidental valve surgery, who had a
hospital discharge date between January 1, 1998 and
December 31, 2004 in the state of New Jersey. Patients
had no prior cancer diagnosis with cancer records dating
back to 1979. Patients with open-heart valve surgery orCABG surgery with incidental valve surgery were ex-
cluded from the study as these patients have very different
propensities for CPB compared to those with isolated
CABG surgeries.
For those with isolated CABG surgery, probabilistic
record linkage was used to match records in several state-
wide registries including 1) the Myocardial Data Acquisi-
tion System (MIDAS), which includes hospital discharge
records for patients with a myocardial infarction and other
invasive cardiovascular procedures who have been admit-
ted to New Jersey non-federal acute care hospitals [8], 2)
the New Jersey Department of Health and Senior Services
Open-Heart Surgery Registry (OHSR), which includes
open-heart surgery data required to be reported by NJ car-
diac surgery hospitals necessary to maintain licensing [9],
and 3) the New Jersey State Cancer Registry (NJSCR),
which is a population-based National Cancer Institute’s
Surveillance, Epidemiology and End Results (SEER) Regis-
try and North American Association of Central Cancer
Registry (NAACCR) and collects data on all cancers diag-
nosed and/or treated in New Jersey [10].
Institutional review board approvals for the study were
obtained from the Rutgers and the Department of Health
and Senior Services. NJSCR data were publically available
for research purposes and access to the data was granted
by NJ State Cancer Epidemiology Services. Access and
permission to use the linked MIDAS and NJ Open Heart
Surgery Registry data were provided by the Cardiovascular
Institute at Robert Wood Johnson Medical School. After
data linkage was complete, data were combined to form a
comprehensive database for analysis, and all personal
identifying information needed for linkage of the registries
were deleted from the source records.
Endpoints
The primary endpoint was cancer-specific mortality.
Cancer-specific case fatality for those with cancers diag-
nosed within 1-year, 2-years, and 4-years of surgery was
also examined, as well as cardiovascular- and other
cause-specific mortality. The main source of vital statis-
tics for the study was MIDAS, which is linked annually
with mortality data obtained from the National Center
for Health Statistics. An additional sensitivity analysis of
cancer-specific mortality was also performed using vital
statistics data from the National Center for Health Sta-
tistics Multiple Cause of Death File, which lists as many
as 20 contributing causes of death in addition to the re-
ported underlying cause of death [11].
Other key secondary endpoints included cancer inci-
dence and stage. Overall cancer incidence was examined
and incidence for a subset of 11 commonly occurring can-
cers, including those thought to be more susceptible to
chronic immune modulation (i.e. skin melanoma, non-
Hodgkin lymphomas, kidney cancer).
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Given the observational nature of the study, propensity
scores were used as an adjustment in the model to help
minimize bias related to differences in baseline risk fac-
tors, as those with and without CPB may differ in import-
ant prognostic factors related to outcome [12]. The
propensity score model was developed using a stepwise lo-
gistic regression with CPB as the outcome variable in the
model. The model was developed with baseline character-
istics reported at the time of the first open-heart surgery.
Univariate modeling was performed to identify potential
confounders and covariates with a significant association
with the outcome of mortality [13,14]. The discriminatory
power of the model was assessed using the area under the
receiver operating characteristic curve (AUC), or C statis-
tic; however, this model diagnostic was not used to guide
variable selection into the propensity score model. Asym-
metric restriction of the propensity score distribution
(‘trimming’) was applied to improve overlap of the pro-
pensity score distribution and improve baseline covariate
balance between the groups.
For cancer-specific mortality and cancer incidence, the
primary analysis was performed using a competing risk
analogue of the Cox Proportional Hazard models [15]. To
account for the correlation among patients within a hos-
pital or surgeon cluster, a robust covariance matrix was
used to compute hazard ratios and 95% confidence inter-
vals as measures of relative risk [16]. The zero time for the
analysis was the date of the first surgery, and patients were
followed until the date of the event (death, cancer inci-
dence) or December 31, 2006 (date of censorship), which-
ever came first. The proportional hazards assumption was
tested using Schoenfeld residuals [17]. Each model was ad-
justed, as applicable, for potential confounders including
age, gender, race, cancer type, stage, time interval between
surgery and cancer diagnosis, type of cancer treatment,
use of blood products during surgery, year of surgery, and
propensity score quantiles. For each analysis, crude and
adjusted hazard ratios are presented. Differences in cancer
stage was examined using a Cochran Armitage trend test.
Logistic and linear regression models, diagnostic test-
ing, and sensitivity analyses were also employed as ap-
propriate. Given the exploratory nature of this research,
no multiplicity adjustments were performed. All analyses
were performed in SAS V9.2 (SAS Institute Inc, Cary,
NC, USA).
Results
Sample and baseline covariates
A total of 48,009 patients who underwent isolated open-
heart CABG surgery with (35,795) and without (12,214)
CPB with extracorporeal circulation (or “pump” proce-
dures) were included in the final analysis. Less than 2%
of patients in the linked database were excluded fromthe analysis due to missing perfusion data or death on
the date of open-heart surgery. The majority of patients
(>99.7%) included in the final analysis had a single open-
heart surgery and the mean perfusion time for surgeries
performed on pump was 86 minutes. Additional baseline
characteristics are summarized in Table 1.
The group with pump procedures included a higher
percentage of men, and those with a higher prevalence
of coronary artery disease, prior CV intervention, number
of diseased vessels, hypertension, diabetes, cardiogenic
shock, and left main disease; whereas, patients with off-
pump procedures were slightly older, included a greater
proportion of Blacks and Hispanics, patients with Medi-
care/Medicaid insurance and those with urgent CABG sur-
gery, and patients with a higher prevalence of peripheral
vascular disease, renal failure, and moderate/severe lung
disease (Table 1). The majority of patients in each group
were taking aspirin and/or beta blockers preoperatively.
The final propensity score model included age, race,
myocardial infarction, number of diseased vessels, prior
intervention, congestive heart failure, hypertension,
smoking, preoperative status (ie, urgency of the proced-
ure), lung disease, peripheral vascular disease, cerebro-
vascular disease, renal failure, ejection fraction, left
main disease, endocarditis, and cardiogenic shock, each
of which was significant in the model (p<0.01,
AUC=0.679 [95% CI: 0.673, 0.685], p<.0001). There was
fairly good overlap in the resulting propensity score dis-
tributions, except for the tail ends (Figure 1). The final
dataset, after asymmetric trimming to improve overlap
of the propensity score distributions and balance
among baseline covariates, included a total of 43,347 or
90% of the original dataset.Cancer incidence and stage
Of the 43,347 patients included in the final analysis, a
total of 2,960 (6.8%) patients were diagnosed with a total
of 3,182 primary cancers (Table 2). The majority of pa-
tients diagnosed with cancer were male (79.2%), white
(87.3%), and the median age at the time of cancer diag-
nosis was 74 yrs. Of those diagnosed with cancer, the
most commonly reported cancers types included prostate
(25.2%), lung and bronchus (15.0%), colorectal (14.1%),
and cancer of the urinary bladder (8.2%).
The risk of developing cancer was proportionally
greater in patients who underwent pump procedures
compared with off-pump procedures (7.2% versus 5.8%,
respectively), but the difference did not achieve statis-
tical significance with or without adjustment for baseline
risk factors (crude RR=1.06 [95% CI: 0.86-1.30, p=0.59],
adjusted RR=1.17 [95% CI: 0.93-1.47, p=0.19]) (Table 2).
These findings correspond to a cancer rate of 3.8 per
100,000 person-years of risk in the group with pump
Table 1 Baseline characteristics for patients with open-heart surgery in New Jersey between 1998–2004, by CPB status
All CABG patientsa (n=48,009)
Pumpb (n=35,795) Off pump (n=12,214)
Length of hospital stay, mean (range) 11 (0–303) 10 (0–175)
Males, n (%) 25,868 (72.7) 8,547 (70.0)
Age, n (%) <50 3,231 (9.0) 1,096 (9.0)
50-59 7,439 (20.8) 2,351 (19.3)
60-69 11,304 (31.6) 3,637 (29.8)
70-79 10,999 (30.7) 3,743 (30.7)
≥80 2,822 (7.9) 1,387 (11.4)
Race/ethnicity, n (%) White 30,030 (83.9) 9,744 (79.8)
Black 1,927 (5.4) 931 (7.6)
Hispanic 1,511 (4.2) 757 (6.2)
Other/unknown 2,327 (6.5) 782 (6.4)
Primary insurance, n (%) Medicare/medicaid 16,254 (45.4) 6,450 (52.8)
Blue cross/commercial 6,021 (17.3) 2,070 (17.0)
HMO 7,801 (21.8) 2,351 (19.3)
Uninsured/indigent 924 (2.6) 366 (3.0)
Self pay 676 (1.9) 205 (1.7)
Other 3,939 (11.0) 772 (6.3)
Preoperative statusc, n (%) Elective 13,428 (37.5) 4,297 (35.2)
Urgent 20,369 (56.9) 7,412 (60.7)
Emergent 1,793 (5.0) 403 (3.3)
Salvage 78 (0.2) 13 (0.1)
Myocardial infarction, n (%) 15,934 (44.5) 5,073 (41.5)
Prior CV intervention, n (%) 8,987 (25.1) 2,823 (23.1)
Diabetes, n (%) 13,069 (36.5) 4,009 (32.8)
Hypertension, n (%) 27,153 (75.9) 8,779 (71.9)
Congestive heart failure, n (%) 5,981 (16.7) 2,034 (16.7)
Cardiogenic shock, n (%) 1,497 (4.2) 253 (2.1)
Endocarditis, n (%) 77 (0.2) 19 (0.2)
Cerebrovascular disease, n (%) 4,042 (11.3) 1,417 (11.6)
Smoke, ever, n (%) 18,724 (52.3) 6,454 (52.8)
Renal failure, n (%) 1,660 (4.6) 691 (5.7)
Lung disease, n (%) Mild 3,427 (9.6) 1,078 (8.8)
Moderate 753 (2.1) 294 (2.4)
Severe 343 (1.0) 181 (1.5)
Peripheral vascular disease, n (%) 5,359 (15.0) 2,019 (16.5)
Disease vessels, n (%) One 958 (2.7) 759 (6.2)
Two 5,721 (16.0) 2,010 (16.5)
Three 23,407 (65.4) 7,699 (63.0)
LM disease (>50% Occlusion), n (%) 10,055 (28.1) 3,208 (26.3)
Ejection fraction (%), n (%) <20% 881 (2.5) 490 (4.0)
20-29% 2,494 (7.0) 725 (6.0)
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Table 1 Baseline characteristics for patients with open-heart surgery in New Jersey between 1998–2004, by CPB status
(Continued)
30-39% 5,002 (14.0) 1,422 (11.7)
40-49% 8,703 (24.3) 2,641 (21.6)
≥50% 18,577 (51.9) 6,963 (56.8)
aincludes patients with ≥1 isolated CABG surgeries; excludes patients with incidental valve surgery .
bincludes patients with ≥1 on-pump procedure prior to incident cancer. Less than 0.2% of patients also had an off-pump procedure.
celective: procedure deferred without increased risk of compromised cardiac outcome; urgent: not elective/emergent, required during same hospitalization to
minimize chance of further clinical deterioration, worsening/sudden chest pain, congestive heart failure, acute myocardial infarction (AMI), anatomy, IABP,
unstable angina with IV nitroglycerin or rest angina; emergent: ischemic dysfunction (ongoing ischemia including rest angina despite maximal medical therapy
(medical and/or IABP), MI within 24 hours before surgery, or pulmonary edema requiring intubation), mechanical dysfunction (shock with or without circulatory
support); emergent salvage: CPR enrout to the operating room or prior to anesthesia induction.
Baseline characteristics were assessed at the time of the first open-heart surgery.
%= n/N patients where n=frequency count in each category and N=total number of subjects.
Due to rounding, sum of all percentages may equal 100%.
CABG= coronary artery bypass graft, CPB=cardiopulmonary bypass (or “pump” procedure).
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the group with off-pump procedures.
Of the 11 tumor-specific analyses performed, there
was an increased risk of skin melanoma [RR=1.66
(95% CI, 1.08-2.55: p=0.02)], lung cancer [RR=1.36
(95% CI, 1.02-1.81: p=0.03)]), and a borderline in-
crease in the relative risk of colorectal cancer (1.22
[95% CI: 0.98-1.53], p=0.08) after adjustment for base-
line risk factors (Table 2). Similar findings were ob-
served using standard Kaplan Meier methods (data
not shown). For those cancers with a reported stage,
there was no significant difference in the stage of
cancers between the groups with and without pump
exposure (p=0.65). Approximately 20% of reported
cancers were metastatic at the time of diagnosis.Figure 1 Boxplot of propensity scores by exposure status and quanti
including a total of 43,347 coronary artery bypass patients. 1 and 0 designaCancer-specific mortality
Of the 43,347 patients with isolated CABG surgery, the
adjusted relative risk of cancer-specific mortality was
1.16 (95% CI: 0.92-1.46, p=0.20) (Table 3). Cardiovascu-
lar and other-cause specific mortality was also increased
for those who underwent pump versus off-pump surgery
(1.15 (95% CI: 0.86-1.55, p=0.34) and 1.20 (95% CI: 0.65-
2.19, p=0.56), respectively. Of those patients with a cancer
diagnosis after surgery, the adjusted risk of cancer-specific
mortality was 1.12 (95% CI: 0.89-1.41, p=0.33) (Table 4). A
Kaplan Meier plot illustrating the risk of cancer-specific
mortality for those patients with cancers diagnosed after
surgery is presented in Figure 2. No trend was observed
for cancers diagnosed within shorter timeframes after sur-
gery (Table 4).les of propensity score distribution. Legend. Final analytical dataset
tes patients with pump and off-pump exposure status, respectively.
Table 2 Relative risk of cancer, including any cancer and tumor-specific cancers
CABG patientsa (n=43,347)
Pumpb (n=33,357) Off Pump (n=9,900) Unadjusted Adjustedc
n %d n %d RRe (95% CI) p-value RRe (95% CI) p-value
Patients ≥1 primary cancerf 2,388 7.2% 572 5.8%
Patients w/tumor-specific cancersg
• Lung and bronchus 369 1.1% 75 0.8% 1.24 (0.94-1.62) 0.125 1.36 (1.02- 1.81) 0.034
• Prostate 609 1.8% 137 1.4% 1.13 (0.85-1.51) 0.401 1.25 (0.92-1.68) 0.149
• Pancreas 63 0.2% 18 0.2% 0.86 (0.57-1.32) 0.495 0.95 (0.62-1.47) 0.820
• Stomach 65 0.2% 23 0.2% 0.73 (0.43-1.22) 0.226 0.80 (0.48-1.35) 0.404
• Breast 100 0.3% 30 0.3% 0.84 (0.52-1.35) 0.467 0.92 (0.57-1.51) 0.752
• Colon/rectum 338 1.0% 79 0.8% 1.11 (0.90-1.38) 0.343 1.22 (0.98-1.53) 0.083
• Kidney/renal pelvis 93 0.3% 25 0.3% 0.95 (0.75-1.21) 0.676 1.05 (0.83- 1.32) 0.698
• Urinary bladder 197 0.6% 45 0.5% 1.07 (0.79-1.45) 0.672 1.18 (0.84-1.66) 0.339
• Corpus uterus 31 0.1% 3 0.0% *** ********* **** *** ********* ****
• Non-hodgkin lymphoma 90 0.3% 23 0.2% 0.94 (0.65-1.35) 0.721 1.03 (0.71- 1.50) 0.874
• Skin melanoma 116 0.3% 19 0.2% 1.50 (0.99-2.27) 0.053 1.66 (1.08- 2.55) 0.022
afinal dataset after asymmetric trimming of the propensity score model to improve overlap of the propensity score distributions for patients with and without CPB
CABG surgery. The final dataset includes 43,347 patients or 90% of the original dataset.
bincludes CABG patients with ≥1 on-pump procedure prior to incident cancer.
cmodel adjusted for age at time of surgery, gender, race, year of surgery, use of blood products, and propensity score.
d%=number of patients with tumor-specific cancer/ total number in group*100.
erisk ratio for pump/off-pump modeled using Cox proportional hazards model with a robust covariance matrix that accounted for survival times for individuals
within a hospital. For patients with multiple primaries, other cancers are censored at the time of occurrence. Competing risk model with regression of exposure
on cause-specific hazard.
fmultiple primary tumor-specific cancers (e.g. prostate, colorectal) may have been reported for any given patient. For the relative risk of any cancer, the first cancer
reported for patients with multiple primaries was used in the time to event analysis.
gfor tumor-specific cancers, other cancers were censored at the time of diagnosis.
*results for cancers with cell count ≤5 were suppressed to as a way to ensure statistical reliability and protect patient confidentiality.
CABG=coronary artery bypass graf, CPB=cardiopulmonary bypass (or “pump” procedure).
Table 3 Cause-specific mortality for isolated open-heart surgery patients with no prior cancer diagnosis, by CPB status
CABG patientsa (n=43,347)
Pumpb Off pump Kaplan Meierc Competing risk modelc
(n=33,357) (n=9,990)
n %d n %d HRe (95% CI) p-value HRe (95% CI) p-value
Cancer-specific mortality
• Unadjusted model 923 2.8% 218 2.2% 1.02 (0.76-1.37) 0.898 1.02 (0.76-1.37) 0.898
• Adjusted modelf 1.13 (0.90-1.42) 0.306 1.16 (0.92-1.46) 0.203
Cardiovascular-specific mortality
• Unadjusted model 2,979 8.9% 754 7.5% 1.01 (0.78-1.31) 0.938 1.01 (0.78-1.31) 0.938
• Adjusted modelf 1.26 (0.89-1.79) 0.186 1.15 (0.86-1.55) 0.344
Other cause-specific mortality
• Unadjusted model 1,862 5.6% 491 4.9% 0.94 (0.73-1.22) 0.658 0.94 (0.73-1.22) 0.658
• Adjusted modelf 1.24 (0.67-2.29) 0.495 1.20 (0.65-2.19) 0.561
afinal dataset after asymmetric trimming of the propensity score model to improve overlap of the propensity score distributions for patients with and without CPB
CABG surgery. The final dataset includes 43,347 patients or 90% of the original dataset.
bincludes patients with ≥1 on-pump procedure prior to incident cancer.
cKaplan-Meier estimate treats failures from competing causes as censored observations; competing risk model with regression of exposure on cause-specific hazard.
d%=number of patients who died / total number in each group*100.
ehazard ratio for pump/off-pump modeled using Cox proportional hazards model with a robust covariance matrix that accounted for survival times for individuals
within a hospital. Zero time for analysis was time of the open-heart surgery.
fmodel adjusted for age at time of surgery, gender, race, year of surgery, use of blood products, and propensity score.
CABG=coronary artery bypass graft, CPB=cardiopulmonary bypass (or “pump” procedure).
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Table 4 Cancer-specific mortality for patients with diagnosis during follow-up, stratified by duration between surgery
and diagnosis
Cancer patientsa (n=2,960)
Pumpb Off pump Kaplan Meierc Competing risk modelc
(n=2,388) (n=572)
n %d n %d HRe (95% CI) p-value HRe (95% CI) p-value
Cancers diagnosed within 1 yr of surgery
Number of patients with cancer 455 126
Patients who died from cancer 155 34.1% 41 32.5%
• Unadjusted model 1.02 (0.72-1.43) 0.932 1.02 (0.72-1.43) 0.932
• Adjusted modelf 1.01 (0.72-1.40) 0.969 1.07 (0.82-.1.41) 0.615
• Sensitivity analysis-MCDg 173 38.0% 43 34.1%
o Unadjusted model 1.08 (0.77-1.52) 0.665 1.08 (0.77-1.52) 0.665
o Adjusted modelf 1.11 (0.83-1.45) 0.514 1.19 (0.94-1.51) 0.148
Cancers diagnosed within 2 yrs of surgery
Number of patients with cancer 868 250
Patients who died from cancer 270 31.3% 75 30.0%
• Unadjusted model 1.00 (0.78-1.28) 0.987 1.00 (0.78-1.28) 0.987
• Adjusted modelf 1.05 (0.76-1.47) 0.762 107 (0.79-1.45) 0.656
• Sensitivity analysis-MCDg 299 34.4% 78 31.2%
o Unadjusted model 1.07 (0.83-1.36) 0.611 1.07 (0.83-1.36) 0.612
o Adjusted modelf 1.10 (0.80-1.50) 0.558 1.15 (0.87-1.54) 0.327
Cancers diagnosed within 4 yrs of surgery
Number of patients with cancer 1,635 448
Patients who died from cancer 484 29.6% 123 27.5%
• Unadjusted model 1.00 (0.79-1.28) 0.980 1.00 (0.80-1.28) 0.980
• Adjusted modelf 1.02 (0.79-1.32) 0.868 109 (0.85-1.39) 0.491
• Sensitivity analysis-MCDg 529 32.4% 132 29.5%
o Unadjusted model 1.02 (0.80-1.29) 0.874 1.02 (0.89-1.29) 0.874
o Adjusted modelf 1.05 (0.80-1.38) 0.678 1.10 (0.87-1.40) 0.417
Cancers diagnosed at any time during follow-up
• Unadjusted model 668 28.0% 141 24.7% 0.96 (0.78-1.17) 0.665 0.96 (0.78-1.17) 0.665
• Adjusted modelf 1.06 (0.85-1.32) 0.595 1.12 (0.89-1.41) 0.330
• Sensitivity analysis-MCDg
o Unadjusted model 730 30.6% 154 26.9% 0.96 (0.78-1.16) 0.648 0.96 (0.78-1.16) 0.648
o Adjusted modelf 1.04 (0.98-1.09) 0.211 1.11 (0.89-1.39) 0.366
afinal dataset after asymmetric trimming of the propensity score model to improve overlap of the propensity score distributions for patients with and without CPB
CABG surgery. The final dataset includes 43,347 patients or 90% of the original dataset.
bincludes patients with ≥1 on-pump procedure prior to incident cancer.
cKaplan-Meier estimate treats failures from competing causes as censored observations; competing risk model with regression of exposure on cause-specific hazard.
d%=number of patients who died / total number in each group*100.
ehazard ratio for pump/off-pump modeled using Cox proportional hazards model with a robust covariance matrix that accounted for survival times for individuals
within a hospital. Zero time for analysis was time of the open-heart surgery.
fmodel adjusted age at time of initial cancer diagnosis, gender, race, cancer type, cancer stage, cancer treatment (e.g. chemotherapy, surgery), duration between
surgery and cancer diagnosis, use of blood products, year of surgery, and propensity score.
gthe analysis used cancer-specific mortality reported as primary cause of death or underlying cause of death using data from the NCHS multiple cause of
death file.
CABG=coronary artery bypass graft, “pump” procedure= CPB=cardiopulmonary bypass.
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Figure 2 Kaplan Meier survival curve for cancer-specific mortality for patients with open-heart surgery and cancer diagnosed during
follow-up, by CPB status Legend: Includes 2,960 cancer patients in study cohort.
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cancer diagnosis was also observed in a separate study
of CPB in patients with a prior cancer diagnosis (data
unpublished). In this separate study, the relative risk for
patients with pump versus off-pump procedures for
cancers diagnosed within a year prior to surgery was
1.05 (95% CI, 0.85-1.30: p=0.67) compared to HR=1.10
(95% CI, 0.87-1.42: p=0.41) and HR=1.07 (95% CI, 0.84-
1.36: p=0.57) for those patients with cancers diagnosed
2 years and 4 years prior to surgery, respectively.
Although the results of each analysis presented herein
demonstrates an increased mortality risk for those with
CPB exposure, none of the results reached statistical signifi-
cance. Similar findings were observed using standard
Kaplan Meier methods and using the NJSCR multiple
cause of death file (Tables 3, 4). For each analysis of cancer-
specific mortality, the proportional hazards assumption
was satisfied.
Discussion
This is the first population-based multicenter cohort study
in patients with underlying cardiovascular disease and no
pre-existing cancer diagnosis which used robust propensity
score modeling to adjust for baseline imbalances and which
accounted for competing risks. Results of this research
show a statistically significant increase in the relative risk of
skin melanoma (RR=1.66: 95% CI, 1.08-2.55: p=0.02), can-
cer of the lung and bronchus (RR=1.36: 95% CI, 1.02-1.81:
p=0.03), and an increase in overall cancer incidence in pa-
tients who underwent isolated CABG surgery with cardio-
pulmonary bypass compared to those patients undergoing
off-pump surgery (RR=1.17: 95% CI, 0.93-1.47: p=0.19).The largest increase in cancer incidence, was observed for
skin melanomas. This is consistent with the underlying hy-
pothesis that immunosuppression and decreased immuno-
surveillance are risk factors for melanoma. Prior studies
have shown an increased risk of skin melanoma with
chronic immune suppression [18]. The possible etiology of
the observed association of CPB with lung cancer develop-
ment is less clear. Although prior studies have shown an in-
creased risk of lung cancer in patients with HIV and heart
transplant recipients, it is unclear if these prior findings are
related to immune suppression, medical surveillance bias,
or an increase in behavioral risk factors such as smoking
for which there may be residual confounding [19,20]. In the
present study, there was no notable difference in the history
of smoking between the pump versus off-pump groups.
Compared to open-heart surgery patients undergoing off-
pump procedures, the results also show a non-statistically
significant increase in the risk of cancer-specific mortality
for patients who underwent cardiopulmonary bypass sur-
gery prior to any diagnosis of cancer 1.16 (95% CI, 0.92-
1.46: p=0.20) as well as a non-statistically significant
increase in the case-fatality rate for those cancer patients
who underwent surgery with cardiopulmonary bypass prior
to the cancer diagnosis (1.12: 95% CI, 0.89-1.41: p=0.33).
No difference was observed in cancer stage at the time of
diagnosis (p=0.65). The time between surgery and cancer
diagnosis, which would serve as the most compelling evi-
dence given its temporal association, did not show any im-
pact on the relative risk of mortality. Even so, there were
too few events to draw any definitive conclusions.
The general strengths of this study includes its
population-based cohort design, the use of medical
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reports by patients or by proxy, the virtually complete ac-
counting of open-heart surgeries given the need for
hospitalization of these patients, and the mandatory
reporting requirements for cancers in the State of New
Jersey. The number of patients with procedures or reloca-
tion outside of New Jersey is assumed to be minimal and
non-differential for patients with and without cardiopul-
monary bypass surgery. Other strengths of this study in-
clude the completeness of vital status records captured
using a variety of methods including, but not limited to, a
review of state and national death files, state taxation files,
hospital discharge files, Medicare and Medicaid files, and
motor vehicle registration records, and the ability to per-
form sensitivity analyses using the National Center for
Health Statistics (NCHS) Multiple Cause of Death file that
captures a cancer diagnosis reported as the primary or
underlying cause of mortality on the death certificate.
Additionally, robust propensity score modeling was used
to help minimize potential confounding, and competing
risk methods were used given that competing risks are of
notable concern due to the age and prevalence of comor-
bidities in this particular patient population.
Although this research entailed one of the most robust
assessments of cancer incidence and cancer-specific mor-
tality in CPB patients to date in a population-based set-
ting, there are design limitations. First, although robust
probabilistic record linkage methods were used to link re-
cords in the different state-wide databases, there is still
the potential for selection bias and information bias result-
ing from this process. As well, the generalizability of this
study is limited given asymmetric trimming of ~10% of
the original database to improve overlap in propensity
score distributions. Additionally, even with the use of pro-
pensity score adjustment for important risk factors, there
is still the chance of imbalances between the groups in
important unmeasured confounders and residual con-
founding due to lack of detailed information collected
for other important risk factors included in the propen-
sity score modeling. Lastly, with no control for false dis-
covery rates and multiple testing, spurious results are
possible and, as such, the results should be interpreted
with caution.
Conclusion
The data suggest there may be some degree of associ-
ation between CPB and cancer progression. However, if
real, the effect is likely to be modest at best. Although
clinical practice guidelines will not likely change based
on these findings, the results may assure clinicians that
the choice of cardiopulmonary bypass should be deter-
mined by other clinical considerations. Further research
may still be warranted to assess whether the transient
immunosuppression associated with CPB can promotethe spread and growth of pre-existing cancer cells with
particular focus on skin melanoma and lung cancer
which had the largest association in this study.
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